Ads
related to: new cancer treatment technology journal submission form
Search results
Results From The WOW.Com Content Network
Also known as laser-assisted immunotherapy, apSTAR is an experimental cancer treatment for solid tumors that uses an autologous vaccine-like approach to stimulate immune responses. Specifically, laser -assisted immunotherapy combines laser-induced in situ tumor devitalization with an immuno adjuvant for local immunostimulation.
Cancer and Metastasis Reviews is a quarterly peer-reviewed medical review journal covering oncology and the development of new cancer treatments. It was established in 1982 and is published by Springer Science+Business Media .
Medical journals are published regularly to communicate new research to clinicians, medical scientists, and other healthcare workers. This article lists academic journals that focus on the practice of medicine or any medical specialty. Journals are listed alphabetically by journal name, and also grouped by the subfield of medicine they focus on.
Apr. 10—DURYEA — New fiber optic cable that can direct very specific light frequencies to kill cancer cells deep in the body without heat. Tiny technological marvels — a dozen could fit in ...
In Clarivate's 2021 Journal Citation Reports indexed by Web of Science, the European Journal of Cancer received an impact factor of 10.002, ranking it 21st journal out of 220 journals in the category cancer research and 26th journal out of 369 journals in the category oncology in the Scimago Journal Ranking. [1] [2]
A huge advancement in cancer treatment after the Food and Drug Administration just approved a type of cell therapy for patients with late-stage melanoma.
Cancer Cell is also interested in publishing clinical investigations, in particular those that lead to establishing new paradigms in the treatment, diagnosis, or prevention of cancers; those that provide important insights into cancer biology beyond what has been revealed by preclinical studies; and those that are mechanism-based proof-of ...
A Memorial Sloan Kettering phase 1 clinical trial revealed an immune response in some pancreatic cancer patients. Study co-author Dr. Vinod Balachandran talks about the impact on future cancer care.